A phase I study will investigate the safety, tolerance and efficacy of CXCR4 modified CAR T cells in patients who failed standard treatment/refractory/relapsed multiple myeloma (NCT04727008) while the CXCR4 antagonist AMD3100 was tested in a variety of tumor types [247]. The gene discussed is CXCR4; the disease is neoplasm.